$LQDA

Manning Paul B sold $12.8M of LQDA (indirect holdings)

Manning Paul B sold 200,000 indirectly-held shares of Liquidia Corp (LQDA) at an average of $63.91 ($62.62–$64.42, $12.78M total) across 5 trades on 2026-06-04.

Original reporting
SEC EDGAR · Manning Paul B
Published Jun 8, 2026, 8:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 200,000 shares at ~$63.91 weighted average, totaling ~$12.78M, with holdings after sale of 798,335 shares.

02

Market read

This is a primary insider-transaction datapoint that can influence short-term sentiment, but the filing contains no new operational or financial catalyst.

03

What to watch

Form 4s often lack context (taxes, estate planning, diversification). Traders should cross-check whether other insiders or major holders are also selling/buying around the same period.

Relevance 7/10Novelty 8/10Timing: Filed June 8, 2026; sale executed June 4, 2026.

Background

The article reports an SEC Form 4 insider transaction for Liquidia Corp director Manning Paul B.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia director Manning Paul B sold $12.78M of LQDA shares via open-market transactions (Form 4), reducing holdings to 798,335 shares.

Expected impact

Likely limited/short-lived impact; any reaction would be sentiment-driven rather than a fundamental repricing catalyst.

Evidence & confidence

The disclosure is primary-source (Form 4) and sizable, but the article provides no accompanying company-specific news (earnings, guidance, trials, deals) and notes no 10b5-1 plan.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical signal provided.

None indicated.

None indicated.

Counterpoint

The sale may reflect diversification, liquidity needs, or pre-planned personal circumstances; without a 10b5-1 plan, it still doesn’t prove negative company outlook.

Key entities

  • Liquidia Corp

    Company whose director insider sale is disclosed on SEC Form 4.

  • Manning Paul B

    Director who sold 200,000 shares of LQDA across five trades on June 4, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.